Clarivate Plc announced that it has entered into a definitive agreement to sell its Life Sciences & Healthcare (LS&H) segment to Altaris LLC, an investment firm focused on healthcare, for $600 million.
Following the transaction, Clarivate will concentrate on its Academia & Government (A&G) and Intellectual Property (IP) segments, positioning itself as a subscription‑first provider of intelligence solutions, workflow software, and technology‑enabled services. Both segments leverage shared content assets and technology platforms, with A&G supporting academic institutions and government organizations, and IP offering data and expertise to help companies manage intellectual property.
Chief Executive Officer Matti Shem Tov stated that the agreement aligns with Clarivate’s Value Creation Plan, which aims to optimize operations, improve sales execution, accelerate innovation, and streamline the portfolio. He indicated that the divestiture would strengthen efficiency, innovation, and customer reach, while enhancing the company’s financial profile.
Executive Vice President and Chief Financial Officer Jonathan Collins noted that the sale would improve Clarivate’s revenue mix, reduce capital intensity, and expand margins. He added that proceeds from the transaction would accelerate debt reduction and provide greater financial flexibility for long‑term growth.
Henry Levy, President of the LS&H segment, explained that the business integrates domain expertise, data assets, and analytical capabilities to support decision‑making across the drug and device lifecycle. He said that under Altaris, the segment would be positioned to build on its foundation and pursue further growth with continued investment.
Under the agreement, Clarivate will receive $500 million in cash at closing, $25 million in deferred cash upon completion of a transition services agreement, and a $75 million seller note. The company intends to use the proceeds to reduce debt.
The transaction is expected to close by the end of 2026, subject to regulatory approvals and customary conditions. Clarivate reaffirmed its full‑year 2026 financial outlook, including LS&H results for the year, which will be reported as discontinued operations beginning in the third quarter. The company also expects to record a non‑cash goodwill impairment of approximately $225–250 million related to the LS&H segment, which will not affect its financial metrics for the year.
Click here to read the original press release.
